Vardenafil hydrochloride

Vardenafil hydrochloride

• Long experience in commercial manufacturing
• Extensive portfolio of PDE-5 inhibitors (Sildenafil, Tadalafil)
• Wide regulatory documentation

Status	Commercial
Therapeutic cat.	Erectile
Polymorphic form	Trihydrate form
CAS No.	330808-88-3
EU DMF readiness
CEP
CHINESE  DMF
JAPANESE DMF
KOREAN  DMF
CANADIAN  DMF
US DMF readiness

Drug description

Vardenafil is an oral therapy for erectile dysfunction that selectively inhibits cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, which activates guanylate cyclase and increases cGMP synthesis in the smooth muscle cells. PDE5 inhibitors like vardenafil prevent the degradation of cGMP, enhancing blood flow into the penis and resulting in an erection. Vardenafil is more potent than sildenafil and tadalafil in inhibiting PDE5, but it has lower selectivity for other PDE isoforms compared to tadalafil.